ahlam1399
07-19-2016, 07:24 PM
Celgene to collaborate with tiny Jounce on cancer immu**therapy
(Reuters) - Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=9SnWQMCUoSo:AI84wP2tJwc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9SnWQMCUoSo:AI84wP2tJwc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=9SnWQMCUoSo:AI84wP2tJwc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9SnWQMCUoSo:AI84wP2tJwc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=9SnWQMCUoSo:AI84wP2tJwc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/9SnWQMCUoSo
(Reuters) - Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=9SnWQMCUoSo:AI84wP2tJwc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9SnWQMCUoSo:AI84wP2tJwc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=9SnWQMCUoSo:AI84wP2tJwc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9SnWQMCUoSo:AI84wP2tJwc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=9SnWQMCUoSo:AI84wP2tJwc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/9SnWQMCUoSo